Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radspherin after CRS and HIPEC in colorectal peritoneal carcinomatosis
2023-508496-37-00Phase 2Authorised
- Sponsor
- Oncoinvent ASA
- Start
- Apr 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of Radspherin in peritoneal carcinomatosis (PC) and colorectal cancer (CRC) (2 arms), sponsored by Oncoinvent ASA. Primary endpoint: Progression-free survival (PFS). Planned start Apr 2024; status: authorised.
02
Drugs
Radspherin
03
Conditions
peritoneal carcinomatosis (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-508496-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508496-37-00.